Clinical Trial Update: Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fulvestrant alone versus fulvestrant plus palbociclib in operable breast cancer responding to fulvestrant has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)

Snippet

Sponsor: International Cancer Research Group, United Arab Emirates | Conditions: Breast Neoplasm Female | Phase 3 | Status: COMPLETED